(March 6, 2020, 1:29 PM EST) -- WASHINGTON, D.C. — A Delaware federal judge took a “shortcut” when construing various disputed claim terms in a patent used in the ulcerative colitis drug “Uceris” and other systems for delivering drugs to the gastrointestinal tract, the patent owner tells the Federal Circuit U.S. Court of Appeals in a March 4 appellant brief (Valeant Pharmaceuticals International, et al. v. Actavis Laboratories Fl. Inc., et al., No. 20-1201, Fed. Cir.)....